Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review

References

• Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: mechanism of action, clinical efficacy, and resistance. J Fungi. 2020;6(4):324–334. doi:10.3390/jof6040324
   Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837. doi:10.1016/S1473-3099(16)00071-2
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Desai A, Kowalski D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–580. doi:10.5414/CP202434
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Marth FM, Maertens J, et al. Impact of mucositis on absorption and systemic drug exposure of isavuconazole. Antimicrob Agents Chemother. 2017;61(6):e00101–e00117. doi:10.1128/AAC.00101-17
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–285. doi:10.1128/AAC.50.1.279-285.2006
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Marres J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–293. doi:10.1128/AAC.50.1.286-293.2006
   PubMed Web of Science ®Google Scholar
• Townsend R, Kato K, Hale C, et al. Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14C-labeled isavuconazonium sulfate in healthy male volunteers. Clin Pharmacol Drug Dev. 2018;7(2):207–216. doi:10.1002/cpdd.376
   PubMed Web of Science ®Google Scholar
• Kably B, Launay M, Derobertmasure A, et al. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166–197. doi:10.1097/FTD.0000000000000952
   PubMed Web of Science ®Google Scholar
• Wolff RF, Moons KGM, Riley RD, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Inter Med. 2019;170(1):51–58. doi:10.7326/M18-1376
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Desai AV, Lu Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60(8):4568. doi:10.1128/AAC.00514-16
   PubMed Web of Science ®Google Scholar
• Desai A, Kovanda L, Kowalski D, et al. Population pharmacokinetics of isavuconazole from Phase 1 and Phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–5491. doi:10.1128/AAC.02819-15
   PubMed Web of Science ®Google Scholar
• Desai A, Schmitt-Hoffmann A, Mujais S, et al. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–3031. doi:10.1128/AAC.02942-15
   PubMed Web of Science ®Google Scholar
• Desai AV, Han D, Kowalski DL, et al. No dose adjustment for isavuconazole based on age or sex. Antimicrob Agents Chemother. 2019;63(6):e02629–18. doi:10.1128/AAC.02629-18
   PubMed Web of Science ®Google Scholar
• Wu X, Venkataramanan R, Rivosecchi RM, et al. Population pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients. Antimicrob Agents Chemother. 2020;64(2):e01728–e01819. doi:10.1128/AAC.01728-19
   PubMed Web of Science ®Google Scholar
• Shirae S, Tsuruya Y, Kozaki T, et al. Population pharmacokinetics, exposure-safety, and probability of target attainment analyses for isavuconazole in Japanese patients with deep-seated mycoses. J Clin Pharmacol. 2023;63(6):704–714. doi:10.1002/jcph.2212
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Pacanowski MA, Bull J, et al. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.61
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110. doi:10.2165/11539220-000000000-00000
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickerman J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–4890. doi:10.1128/AAC.00319-09
   PubMed Web of Science ®Google Scholar
• Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy. Antimicrob Agents Chemother. 2019;63(12):e01085–19. doi:10.1128/AAC.01085-19
   PubMed Web of Science ®Google Scholar
• Zhao Y, Seelhammer TG, Barreto E, et al. Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation. Pharmacotherapy. 2020;40(1):89–95. doi:10.1002/phar.2348
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53. doi:10.1002/cpdd.285
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Desai A, Han D, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):93–101. doi. doi:10.1002/cpdd.282
   PubMed Web of Science ®Google Scholar